Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (2)

Trial Status

Recruiting2
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04629729Phase 1Active Not Recruiting

FT819 in Subjects With B-cell Malignancies

NCT06754267Phase 2RecruitingPrimary

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

NCT06742515Phase 2RecruitingPrimary

Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

Showing all 3 trials

Research Network

Activity Timeline